Astrazeneca (AZN) Total Current Liabilities (2015 - 2026)

Astrazeneca's Total Current Liabilities history runs 12 years deep, the most recent figure standing at -$32.6 billion for Q1 2026.

• In Q1 2026, Total Current Liabilities fell 11.81% year-over-year to -$32.6 billion; the TTM figure through Mar 2026 stood at -$32.6 billion (down 11.81% YoY), while the FY2025 annual figure was -$30.6 billion, down 209.87% from the prior year.
• Total Current Liabilities was -$32.6 billion for Q1 2026 at Astrazeneca, down from -$30.6 billion in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $30.5 billion in Q4 2023 to a low of -$34.1 billion in Q3 2025.
• Historically, Total Current Liabilities has averaged -$18.1 billion across 5 years, with a median of -$26.4 billion in 2023.
• The sharpest annual moves came in 2022 and 2025: Total Current Liabilities rose 16.37% in 2022, then tumbled 209.87% in 2025.
• A 5-year view of Total Current Liabilities shows it stood at $26.3 billion in 2022, then advanced by 16.16% to $30.5 billion in 2023, then declined by 8.76% to $27.9 billion in 2024, then sank by 209.87% to -$30.6 billion in 2025, then dropped by 6.38% to -$32.6 billion in 2026.
• The last three Total Current Liabilities figures came in at -$32.6 billion (Q1 2026), -$30.6 billion (Q4 2025), and -$34.1 billion (Q3 2025), per Business Quant data.